Complement Inhibition in Severe COVID-19 Acute Respiratory Distress Syndrome

Frontiers in Pediatrics

article

Sharmila Raghunandan¹  Satheesh Chonat¹  Cassandra D. Josephson³  Hans Verkerke³  W. Matthew Linam⁴  Treva C. Ingram¹  Patricia E. Zerra²  Connie M. Arthur³  Sean R. Stowell³  Michael Briones¹ 

[1] Department of Pediatrics, Emory University School of Medicine, United States;Aflac Cancer and Blood Disorders Center, United States;Center for Transfusion and Cellular Therapy, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, United States;Division of Pediatric Infectious Diseases, Emory University School of Medicine and Children's Healthcare of Atlanta, United States;Division of Pediatric Intensive Care Unit, Children's Healthcare of Atlanta, United States;Joint Program in Transfusion Medicine, Department of Pathology, Harvard Medical School, United States

关键词: complement;    COVID;    19;    SARS-CoV-2;    eculizumab;    acute respiratory distress syndrome (ARDS);    children;    pediatric;   

DOI  :  10.3389/fped.2020.616731

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Most children with COVID-19 have asymptomatic or mild illness. Those who become critically ill suffer from acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI). The rapid deterioration of lung function has been linked to microangiopathic and immune-mediated processes seen in the lungs of adult patients with COVID-19. The role of complement-mediated acute lung injury is supported by animal models of SARS-CoV, evaluation of lung tissue in those who died from COVID-19 and response of COVID-19 ARDS to complement inhibition. We present a summary of a child with COVID-19 disease treated with convalescent plasma and eculizumab and provide a detailed evaluation of the inflammatory pathways.

【 授权许可】

CC BY